An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies

46OA Phase 1a/2a trial of AVID100, an anti-EGFR antibody-drug conjugate

(2018) A Tolcher et al.   ANNALS OF ONCOLOGY

The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine

(2018) Jenny M. Riley et al.   CANCER

CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma

(2017) Jin Zhou et al.   Nature Communications

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

(2017) et al.   JAMA Oncology

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models

(2016) F. Li et al.   CANCER RESEARCH

Development of AVID100, a novel antibody–drug conjugate for the treatment of EGFR expressing solid tumors

(2016) M. O'Connor-McCourt et al.   EUROPEAN JOURNAL OF CANCER

Antibodies as stratagems against cancer

(2016) Louis Papageorgiou et al.   Molecular BioSystems

ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

(2016) A. C. Phillips et al.   MOLECULAR CANCER THERAPEUTICS

Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma

(2015) GANG LIN et al.   Oncology Letters

Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy

(2014) Ravi V. J. Chari et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Identification of genomic alterations in oesophageal squamous cell cancer

(2014) Yongmei Song et al.   NATURE

Markedly Enhanced Permeability and Retention Effects Induced by Photo-immunotherapy of Tumors

(2012) Kohei Sano et al.   ACS Nano

A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC)

(2012) Se Hyun Kim et al.   LUNG CANCER

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

(2012) Andrea Cavazzoni et al.   Molecular Cancer

Pharmacokinetic Considerations for Antibody Drug Conjugates

(2012) Kedan Lin et al.   PHARMACEUTICAL RESEARCH

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma

(2011) J. A. Chan et al.   ANNALS OF ONCOLOGY

Brentuximab Vedotin (SGN-35)

(2011) J. Katz et al.   CLINICAL CANCER RESEARCH

Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent

(2008) C. R. Patra et al.   CANCER RESEARCH